Neutropenia and intellectual disability are hallmarks of biallelic and de novo CLPB deficiency.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
09 2021
Historique:
received: 21 09 2020
accepted: 15 04 2021
revised: 15 04 2021
pubmed: 19 6 2021
medline: 21 10 2021
entrez: 18 6 2021
Statut: ppublish

Résumé

To investigate monoallelic CLPB variants. Pathogenic variants in many genes cause congenital neutropenia. While most patients exhibit isolated hematological involvement, biallelic CLPB variants underlie a neurological phenotype ranging from nonprogressive intellectual disability to prenatal encephalopathy with progressive brain atrophy, movement disorder, cataracts, 3-methylglutaconic aciduria, and neutropenia. CLPB was recently shown to be a mitochondrial refoldase; however, the exact function remains elusive. We investigated six unrelated probands from four countries in three continents, with neutropenia and a phenotype dominated by epilepsy, developmental issues, and 3-methylglutaconic aciduria with next-generation sequencing. In each individual, we identified one of four different de novo monoallelic missense variants in CLPB. We show that these variants disturb refoldase and to a lesser extent ATPase activity of CLPB in a dominant-negative manner. Complexome profiling in fibroblasts showed CLPB at very high molecular mass comigrating with the prohibitins. In control fibroblasts, HAX1 migrated predominantly as monomer while in patient samples multiple HAX1 peaks were observed at higher molecular masses comigrating with CLPB thus suggesting a longer-lasting interaction between CLPB and HAX1. Both biallelic as well as specific monoallelic CLPB variants result in a phenotypic spectrum centered around neurodevelopmental delay, seizures, and neutropenia presumably mediated via HAX1.

Identifiants

pubmed: 34140661
doi: 10.1038/s41436-021-01194-x
pii: S1098-3600(21)05097-8
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
HAX1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1705-1714

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics.

Références

Skokowa, J., Dale, D. C., Touw, I. P., Zeidler, C. & Welte, K. Severe congenital neutropenias. Nat. Rev. Dis. Primers. 3, 17032 (2017).
doi: 10.1038/nrdp.2017.32
Wortmann, S. B. et al. Treating neutropenia and neutrophil dysfunction in glycogen storage disease IB with an SGLT2-inhibitor. Blood. 136, 1033–1043 (2020).
Boztug, K. et al. HAX1 mutations causing severe congenital neuropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRI. Am. J. Med. Genet. A. 152a, 3157–3163 (2010).
doi: 10.1002/ajmg.a.33748
Wortmann, S. B. et al. CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder. Am. J. Hum. Genet. 96, 245–257 (2015).
doi: 10.1016/j.ajhg.2014.12.013
Capo-Chichi, J. M. et al. Disruption of CLPB is associated with congenital microcephaly, severe encephalopathy and 3-methylglutaconic aciduria. J. Med. Genet. 52, 303–311 (2015).
doi: 10.1136/jmedgenet-2014-102952
Pronicka, E. et al. A scoring system predicting the clinical course of CLPB defect based on the foetal and neonatal presentation of 31 patients. J. Inherit. Metab. Dis. 40, 853–860 (2017).
doi: 10.1007/s10545-017-0057-z
Liberek, K., Lewandowska, A. & Zietkiewicz, S. Chaperones in control of protein disaggregation. EMBO J. 27, 328–335 (2008).
doi: 10.1038/sj.emboj.7601970
Chen, X. et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 9, 890–909 (2019).
doi: 10.1158/2159-8290.CD-19-0117
Yoshinaka, T. et al. Structural basis of mitochondrial scaffolds by prohibitin complexes: insight into a role of the coiled-coil region. iScience. 19, 1065–1078 (2019).
Mroz, D. et al. CLPB (caseinolytic peptidase B homolog), the first mitochondrial protein refoldase associated with human disease. Biochim. Biophys. Acta Gen. Subj. 1864, 129512 (2020).
doi: 10.1016/j.bbagen.2020.129512
Cupo, R. R. & Shorter, J. Skd3 (human ClpB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations. eLife. 9, e55279 (2020).
Pellegrini, L. et al. PAMP and PARL, two novel putative metalloproteases interacting with the COOH-terminus of Presenilin-1 and -2. J. Alzheimers Dis. 3, 181–190 (2001).
doi: 10.3233/JAD-2001-3203
Suzuki, Y. et al. HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J. Immunol. 158, 2736–2744 (1997).
pubmed: 9058808
Kovacs-Nagy, R. et al. HTRA2 defect: a recognizable inborn error of metabolism with 3-methylglutaconic aciduria as discriminating feature characterized by neonatal movement disorder and epilepsy—report of 11 patients. Neuropediatrics. 49, 373–378 (2018).
doi: 10.1055/s-0038-1667345
Wagner, M. et al. Mitochondrial DNA mutation analysis from exome sequencing—a more holistic approach in diagnostics of suspected mitochondrial disease. J. Inherit. Metab. Dis. 42, 909–917 (2019).
doi: 10.1002/jimd.12109
Rius, R. et al. Biparental inheritance of mitochondrial DNA in humans is not a common phenomenon. Genet. Med. 21, 2823–2826 (2019).
doi: 10.1038/s41436-019-0568-0
Norby, J. G. Coupled assay of Na+,K+-ATPase activity. Methods Enzymol. 156, 116–119 (1988).
doi: 10.1016/0076-6879(88)56014-7
Riley, L. G. et al. The diagnostic utility of genome sequencing in a pediatric cohort with suspected mitochondrial disease. Genet. Med. 22, 1254–1261 (2020).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 581, 434–443 (2020).
doi: 10.1038/s41586-020-2308-7
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 536, 285–291 (2016).
doi: 10.1038/nature19057
Spiegel, R. et al. Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy associated with a homozygous OPA1 mutation. J. Med. Genet. 53, 127–131 (2016).
doi: 10.1136/jmedgenet-2015-103361
Harel, T. et al. Recurrent de novo and biallelic variation of ATAD3a, encoding a mitochondrial membrane protein, results in distinct neurological syndromes. Am. J. Hum. Genet. 99, 831–845 (2016).
doi: 10.1016/j.ajhg.2016.08.007
Sinha, S., Zhu, Q. S., Romero, G. & Corey, S. J. Deletional mutation of the external domain of the human granulocyte colony-stimulating factor receptor in a patient with severe chronic neutropenia refractory to granulocyte colony-stimulating factor. J. Pediatr. Hematol. Oncol. 25, 791–796 (2003).
doi: 10.1097/00043426-200310000-00010
Triot, A. et al. Inherited biallelic CSF3R mutations in severe congenital neutropenia. Blood. 123, 3811–3817 (2014).
doi: 10.1182/blood-2013-11-535419
Deville, C., Franke, K., Mogk, A., Bukau, B. & Saibil, H. R. Two-step activation mechanism of the ClpB disaggregase for sequential substrate threading by the main ATPase motor. Cell Rep. 27, 3433–3446.e3434 (2019).
doi: 10.1016/j.celrep.2019.05.075
Gates, S. N. et al. Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104. Science. 357, 273–279 (2017).
doi: 10.1126/science.aan1052
DeSantis, M. E. et al. Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell. 151, 778–793 (2012).
doi: 10.1016/j.cell.2012.09.038
Desantis, M. E. et al. Conserved distal loop residues in the Hsp104 and ClpB middle domain contact nucleotide-binding domain 2 and enable Hsp70-dependent protein disaggregation. J. Biol. Chem. 289, 848–867 (2014).
doi: 10.1074/jbc.M113.520759
Sander, C. & Schneider, R. Database of homology-derived protein structures and the structural meaning of sequence alignment. Proteins. 9, 56–68 (1991).
doi: 10.1002/prot.340090107

Auteurs

Saskia B Wortmann (SB)

University Children's Hospital, Paracelsus Medical University (PMU), Salzburg, Austria. s.wortmann@salk.at.
Radboud Center for Mitochondrial Medicine, Department of Pediatrics, Amalia Children's Hospital, Radboudumc, Nijmegen, The Netherlands. s.wortmann@salk.at.
United for Metabolic Diseases (UMD), Amsterdam, The Netherlands. s.wortmann@salk.at.

Szymon Ziętkiewicz (S)

Intercollegiate Faculty of Biotechnology, University of Gdansk, Gdansk, Poland.

Sergio Guerrero-Castillo (S)

University Children's Research@Kinder-UKE, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

René G Feichtinger (RG)

University Children's Hospital, Paracelsus Medical University (PMU), Salzburg, Austria.

Matias Wagner (M)

Institute of Neurogenomics, Helmholtz Zentrum München, Neuherberg, Germany.
Institute of Human Genetics, Technical University of Munich, Munich, Germany.

Jacqui Russell (J)

Genetic Metabolic Disorders Service, Sydney Children's Hospital Network, Randwick, NSW, Australia.

Carolyn Ellaway (C)

Genetic Metabolic Disorders Service, Sydney Children's Hospital Network, Randwick, NSW, Australia.
Discipline of Child & Adolescent Health; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Discipline of Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Dagmara Mróz (D)

Intercollegiate Faculty of Biotechnology, University of Gdansk, Gdansk, Poland.

Hubert Wyszkowski (H)

Intercollegiate Faculty of Biotechnology, University of Gdansk, Gdansk, Poland.

Denisa Weis (D)

Department of Medical Genetics, Med Campus IV, Kepler University Hospital, Johannes Kepler University, Linz, Austria.

Iris Hannibal (I)

Division of Pediatric Neurology, Developmental Medicine and Social Pediatrics, Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany.

Celina von Stülpnagel (C)

Division of Pediatric Neurology, Developmental Medicine and Social Pediatrics, Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany.
Institute for Transition, Rehabilitation and Palliation, Paracelsus Medical University, Salzburg, Austria.

Alfredo Cabrera-Orefice (A)

Center for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences (RIMLS), Nijmegen, The Netherlands.

Uta Lichter-Konecki (U)

Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Jenna Gaesser (J)

Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Randy Windreich (R)

Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Division of Blood and Marrow Transplantation and Cellular Therapies, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.

Kasiani C Myers (KC)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Robert Lorsbach (R)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Russell C Dale (RC)

Neuroimmunology Group, Institute for Neuroscience and Muscle Research, Kids Research Institute at the Children's Hospital at Westmead, University of Sydney, Sydney, Australia.

Søren Gersting (S)

University Children's Research@Kinder-UKE, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Carlos E Prada (CE)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

John Christodoulou (J)

Discipline of Child & Adolescent Health; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Discipline of Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Murdoch Children's Research Institute and Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.

Nicole I Wolf (NI)

Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands.
Amsterdam Neuroscience, Vrije Universiteit, Amsterdam, The Netherlands.

Hanka Venselaar (H)

Center for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences (RIMLS), Nijmegen, The Netherlands.

Johannes A Mayr (JA)

University Children's Hospital, Paracelsus Medical University (PMU), Salzburg, Austria.

Ron A Wevers (RA)

United for Metabolic Diseases (UMD), Amsterdam, The Netherlands.
Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH